Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".